MSD Archives

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck’s (MSD) anti-PD-1 therapy (Keytruda), with Affimed’s proprietary drug for the treatment of patients with Hodgkin lymphoma. The phase Ib trial will focus on patients whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

merck msd cancer immunoncology complix alphabody

News and Trends 7 Jan 2016

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery collaboration with Merck Sharp & Dohme (MSD). Under the terms of the agreement, Complix will use its proprietary Alphabody platform to tackle two intra-cellular cancer targets. One example is the myeloid leukemia cell-1 protein (MCL-1), […]

January 7, 2016 - 2 minutesmins - By Dani Bancroft

blood cells transport drugs rubius therapeutics flagship erytech pku

News and Trends 14 Dec 2015

Red Blood Cells to Carry Drugs? A US Start-Up Inspired by French Biotech to Focus on Rare Metabolic Disease

Erytech (France) is working on a drug-transportation system using red blood cells. Now US Rubius Therapeutics joins Erytech on this new approach to drug delivery, backed by the huge VC in the States; Flagship Ventures. Flagship Ventures has yet again shown its comprehensive portfolio in biotech through another EU inspired Biotech start-up. Rubius Therapeutics in […]

December 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease. Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Oct 2015

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Monday: Manfred Horst on MSD, Biosimilars, KEYTRUDA and Merck & Co.’s rich history Tuesday: An Insider’s experience at the iGEM Giant Boston Jamboree 2015 Wednesday: Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize! Thursday: The Future Biotech Lab Bench: My experience of the cutting edge-tech at LABVOLUTION Friday: Alzheimer’s Disease: Phase III breakthrough Tau-therapy earns […]

October 10, 2015 - 1 minutemin - By Philip Hemme

News and Trends 8 Oct 2015

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is developed for a much more specific immunohistochemical alternative to the traditional Rodent equivalents. Now the most recent generation of mAbs from this platoform is able to detect PD-L1 tumor proteins for immuno-oncology research. The conventional […]

October 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Medicine Nobel Prize for Parasite Drug Discoveries which saved Billions

The Nobel Prize for Medicine and Physiology has been jointly awarded to Youyou Tu (the first ever Chinese recipient of a Nobel Prize in this category) for discovering the malarial medicine Artemisinin, and to William C. Campbell and Satoshi Ōmura, for their pioneering work in developing a major parasitic round worm disease drug, Ivermectin. These […]

October 5, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn […]

October 5, 2015 - 6 minutesmins - By Julie Lellouche

future biomarkers immuno oncology lymphocytes

News and Trends 31 Aug 2015

Review: The Future of Biomarkers in Immuno-Oncology

Immuno-oncology is a Biotech field that is more than just hype – it could solve one of humanity’s biggest health challenges: Cancer. In order to bring more effective treatments with fewer side-effects, Biomarkers will play a key role. I wanted to get an expert view on the subject, so I called Bernhard Sixt, CEO of the […]

August 31, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Using camel antibodies as drugs, sounds crazy? Belgian Ablynx is exactly doing that and has been very successful so far. It’s now moving to the next step. It already signed a €1.7Bn deal with Merck & Co. in February 2014 and now upgrades it to a gigantic €5.7Bn! Ablynx is a biotech company developing Nanobodies for immune-oncology […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us